Status:

COMPLETED

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Dana-Farber Cancer Institute

Brigham and Women's Hospital

Conditions:

Prostate Cancer

Adenocarcinoma of the Prostate

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with pro...

Detailed Description

* Patients will be randomized to either receive Atrasentan alone or Atrasentan plus Zometa. * Patients receiving Atrasentan alone will receive this drug in pill form once daily for 12 weeks. Patients ...

Eligibility Criteria

Inclusion

  • Histologically confirmed adenocarcinoma of the prostate
  • History of bilateral orchiectomy or current treatment with a GnRH agonist or antagonist
  • Radiographically documented bone metastases
  • Disease progression according to criteria from the PSA Working Group

Exclusion

  • Prior treatment with Atrasentan or Zometa within one year
  • Serum creatinine \> 2.0mg/dL
  • Documented cardiovascular disability status of New York Heart Association Class 2
  • Treatment with chemotherapy, radiation, steroids, estrogens, or PC-SPES within 6 weeks
  • Treatment with bisphosphonates or radiopharmaceuticals within 12 weeks
  • History of Paget's disease, hyperthyroidism, hyperparathyroidism, Cushing's syndrome, hyperprolactinemia or other disorder associated with metabolic bone disease.

Key Trial Info

Start Date :

December 1 2001

Trial Type :

INTERVENTIONAL

End Date :

December 1 2006

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT00181558

Start Date

December 1 2001

End Date

December 1 2006

Last Update

May 10 2010

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Massachusetts General Hospital

Boston, Massachusetts, United States, 02114

2

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone | DecenTrialz